Navigation Links
SuperGen Reports 2008 Second Quarter Financial Results
Date:8/4/2008

xpectations regarding the anticipated reduction in operating expenses as a result of the anticipated closure of SuperGen's European operations, expectations regarding the filing of a second IND with the FDA, as well as SuperGen's expectations and successful development of all its pipeline products. Important factors that could cause actual results to differ materially from the expectations reflected in the forward-looking statements include, but are not limited to, risks and uncertainties related to the achievement of developmental milestones with respect to the compounds acquired in the Montigen acquisition, the research and development of MP-470, S-110 or SGI-1776, the satisfaction of the contingencies related to the sale of the worldwide rights to Nipent to Mayne Pharma, and the ability of MGI to generate global sales of Dacogen. In general, our future success is dependent upon numerous factors, including our ability to generate pre-clinical development candidates for selection into clinical testing, obtaining regulatory approval of product development programs, conducting and completing clinical trials and obtaining regulatory approval of our products and product candidates, and creating opportunities for future commercialization of compounds. Our future revenue and operating and net income or loss could be worse than anticipated if demand for our products is less than expected, or if the introduction of new products is delayed, for any reason, including regulatory delay. References made to the discussion of risk factors are detailed in the Company's filings with the Securities and Exchange Commission including reports on its most recently filed Form 10-K and Form 10-Q. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update or revise the information contained in any such forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:

Timothy L.
'/>"/>

SOURCE SuperGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Dr. Audrey F. Jakubowski of SuperGen Retires as Chief Regulatory and Quality Officer
2. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
3. SuperGen to Announce 2007 Fourth Quarter and Fiscal Year-End Financial Results March 3, 2008
4. SuperGen Reports 2007 Fourth Quarter and Annual Financial Results
5. SuperGen to Announce 2008 First Quarter Financial Results April 28, 2008
6. SuperGen to Webcast 3rd Annual Analyst Day on April 29, 2008
7. SuperGen Reports 2008 First Quarter Financial Results
8. SuperGen to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 29, 2008
9. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
10. QMed, Inc. Reports July Medicare SNP Enrollments
11. Phlo Affiliate Reports Expanded Coverage to Oregon Border
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... device," Nobel laureate Herbert Kroemer famously observed, referring ... the junctures where layers of different materials meet. ... between layers of metal oxides are becoming increasingly ... spintronics, high-temperature superconductors, ferroelectrics and multiferroics. Realizing the ...
(Date:1/15/2014)... Jan. 15, 2014   Niagara Thermal Products is ... Buffalo BioBlower Technologies LLC ("B3") as the critical thermal ... award from the Army Corps of Engineers.  B3 has ... all biological contaminants and destroys VOCs and other chemical ...
(Date:1/15/2014)... SAN JOSE, California , January 15, 2014 ... for cancer, today announced the appointment of Thomas C Reynolds ... over 20 years, development experience gained in the biotechnology industry, ... "I am delighted to welcome Tom at this transformative ...
(Date:1/15/2014)... A study has been launched to test whether ... could help to tackle the problem of obesity.  This unique ... surgery based in Stowmarket) and academics at University Campus Suffolk ... technology, which is inspired by equipment used to collect data ...
Breaking Biology Technology:A deeper look at interfaces 2Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4
... 19, 2011 OptiScan Biomedical Corporation, a developer ... in intensive care units (ICU), today announced that ... has received CE Mark certification for use in ... the OptiScanner has met all relevant European Union ...
... The ALS Therapy Development Institute (ALS TDI) and ... their current research collaboration agreement to test additional ... stop the progression of Amyotrophic Lateral Sclerosis (ALS, ... collaboration is based on encouraging results from early-stage ...
... LA JOLLA, CA September 15, 2011 Researchers at ... which certain viruses such as influenza trigger a type of ... This severe immune reactioncalled a "cytokine storm"floods the tiny ... blocking off airways and damaging body tissues and organs. Cytokine ...
Cached Biology Technology:OptiScan Biomedical Receives CE Mark for OptiScanner Automatic Bedside Glucose Monitoring System 2OptiScan Biomedical Receives CE Mark for OptiScanner Automatic Bedside Glucose Monitoring System 3OptiScan Biomedical Receives CE Mark for OptiScanner Automatic Bedside Glucose Monitoring System 4ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies 2ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies 3Scripps Research team discovers treatable mechanism responsible for often deadly response to flu 2Scripps Research team discovers treatable mechanism responsible for often deadly response to flu 3
(Date:7/9/2014)... be able to cope with the rising salinity of Arctic ... today is best known for its tundra and polar bear ... 38 million years ago during what is known as the ... temperate forest with brackish water, home to a variety of ... giant tortoises. Much of what is known about the region ...
(Date:7/9/2014)... be on the verge of an economy driven by methane, ... coal and is undergoing a production boom. It has poised ... research is casting serious doubts over just how climate-friendly it ... News (C&EN), the weekly news magazine of the American ... correspondent at C&EN, explains that when burned as a fuel ...
(Date:7/9/2014)... Cholinergic inhibitors and N-methyl-D-aspartate receptor antagonists can ... fail to affect irreversible cognitive dysfunction and ... brain. Amyloid beta peptide (Aβ) vaccines reduced ... disease (AD) transgenic mouse model, and significantly ... Cao and his team, First Affiliated Hospital ...
Breaking Biology News(10 mins):Shark teeth analysis provides detailed new look at Arctic climate change 2Shark teeth analysis provides detailed new look at Arctic climate change 3
... the frontal cortex in adults, researchers have shown that this ... actions. , It has been known for over 100 ... left frontal cortex, he or she often suffers difficulties in ... impairments, it has been difficult for researchers to test the ...
... high levels of antibodies against the Epstein-Barr virus, the ... likely to develop multiple sclerosis 15 to 20 years ... will appear in the June 2006 print issue of ... Researchers have long suspected that external factors may influence ...
... The cholesterol-lowering medications called statins do not appear to ... to a meta-analysis of previous studies in the January ... that statins reduce the risk of developing cancer, the ... "Statins have been studied in numerous large-scale, randomized, ...
Cached Biology News:Big hips, big belly? It's in your genes, Joslin-led study shows 2Statins have neutral effect on risk of cancer 2
... The IHC Select Immunophosphatase Secondary Detection System ... IHC Select Prediluted Primary Antibody reagents, which ... qualitative identification of antigens by light microscopy ... Secondary Detection System may also be used ...
... FLISP Assay with SR-101 Labeled Substrates ... • Accurately measure serine protease activation ... • B-Bridge's FLISP Kits utilize cell-permeable, ... (FLISPs) to measure chymotrypsin-like activity in ...
From the company that first brought you the chromatin immunoprecipitation (ChIP) kit, a new and improved kit, EZ-ChIP, is now available to make your experiments easier, quicker, and most importantly,...
The PDS-1000 He Hepta system includes the PDS-1000 He biolistic system and the Hepta adaptor....
Biology Products: